Skip to main content
Caplight Logo









ART BioScience

ART BioScience

Private
IsraelHealthcare & Life Scienceshttps://www.artbioscience.com/

Last Round

Series B

Jul 29, 2025

Total Funding Raised

$245M

Company Overview

ART BioScience is a biotechnology company that develops mRNA-based therapeutics and gene-editing therapies for the treatment of Duchenne muscular dystrophy and other rare genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mRNA therapeuticslipid nanoparticleLNPDuchenne Muscular DystrophyDMDgene editingCRISPR-Cas9protein replacement therapydrug delivery technologygenetic medicinebiotech startuporphan diseasedrug discoverypre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ART BioScience Comparables

Compare ART BioScience with similar companies based on industry and business-model similarity.

ART BioScience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Spot Biosystems
82%
Entrada Therapeutics
70%
Solid Biosciences Inc.
70%

ART BioScience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 29, 2025
Series ADec 7, 2023
SeedJun 1, 2023

ART BioScience Investors

Notable investors and investment history

ART BioScience investors
InvestorRounds
Omega FundsSeries A, Series B, Seed
B Capital GroupSeries B
Alexandria Venture InvestmentsSeries B
F-Prime CapitalSeries A, Series B, Seed
Sofinnova InvestmentsSeries B
Qatar Investment AuthoritySeries B
Third Rock VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2025

    $132M round led by B Capital Group and Sofinnova Investments.

  • Dec 7, 2023

    $90M round led by Third Rock Ventures

ART BioScience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ART BioScience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ART BioScience's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Year Founded2015
Last FundingJul 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?